Burling Wealth Partners’s AbbVie ABBV Stock Holding History

Burling Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.8M	Sell	49,534 -386	-0.8%	-$85.6K	1.74%	15
2025 Q4	$11.4M	Buy	49,920 +1,849	+4%	+$421K	1.77%	17
2025 Q3	$11.1M	Buy	48,071 +1,300	+3%	+$265K	1.84%	15
2025 Q2	$8.68M	Buy	46,771 +2,693	+6%	+$500K	1.6%	16
2025 Q1	$9.24M	Buy	44,078 +4,172	+10%	+$811K	1.94%	12
2024 Q4	$7.09M	Buy	+39,906	New	+$7.34M	1.45%	14

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Burling Wealth Partners's ABBV Position: Q1 2026 in Review

Burling Wealth Partners reduced its AbbVie (ABBV) stake by 0.77% in Q1 2026, selling an estimated $85.6K and leaving 49,534 shares worth $10.8M. The position accounts for 1.74% of the portfolio, ranked #15.

Burling Wealth Partners first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $11.4M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Burling Wealth Partners held 49,534 shares of AbbVie worth $10.8M as of Q1 2026.
Burling Wealth Partners sold 386 AbbVie shares in Q1 2026, an estimated $85.6K.
AbbVie made up 1.74% of Burling Wealth Partners's portfolio in Q1 2026, its #15 holding.
Burling Wealth Partners first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
Burling Wealth Partners's AbbVie position peaked at $11.4M in Q4 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Burling Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.